Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.

Landau, H

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. [electronic resource] - Leukemia Apr 2013 - 823-8 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

1476-5551

10.1038/leu.2012.274 doi


Adult
Aged
Amyloidosis--drug therapy
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Boronic Acids--administration & dosage
Bortezomib
Dexamethasone--administration & dosage
Female
Humans
Male
Melphalan--administration & dosage
Middle Aged
Pyrazines--administration & dosage
Stem Cell Transplantation